Ac­celeron scraps dalanter­cept af­ter it flunks a PhII test for kid­ney can­cer

Ac­celeron will not be get­ting any help from dalanter­cept as it works to build con­fi­dence in its pipeline.

The Cam­bridge, MA-based biotech says their an­gio­gen­e­sis drug flopped in a Phase II study for kid­ney can­cer that en­rolled 131 pa­tients. Not on­ly was their no sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for their drug com­bined with ax­i­tinib, ver­sus the stan­dard of care alone, the con­firmed ob­jec­tive re­sponse rate was a lit­tle low­er for Ac­celeron’s drug — 19% com­pared to 25% for the con­trol arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.